NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,409.74 +202.61 (+1.11%) CRUDE OIL
79.16 +0.21 (+0.27%) GOLD FUTURES
2,310.30 +0.70 (+0.03%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
47,651.29 +1,853.19 (+4.05%)
BIO Sep 2024 450.000 call
| Previous close | 6.00 |
| Open | 6.00 |
| Bid | 5.10 |
| Ask | 11.80 |
| Strike | 450.00 |
| Expiry date | 2024-09-20 |
| Day's range | 6.00 - 6.00 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
ZacksEarnings Preview: National Vision (EYE) Q1 Earnings Expected to Decline
National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireBio-Rad’s Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare Conference
HERCULES, Calif., May 01, 2024--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Operating Officer Andy Last and Chief Financial Officer Roop K. Lakkaraju will participate in a fireside chat event during the RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 2:05 PM Eastern Time (11:05 AM Pacific Time).
ZacksAnalysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
